CY1118934T1 - Παρασκευη ενεργης ακρως φωσφορυλιωμενης ανθρωπινης ν-ακετυλογαλακτοζαμινης-6-σουλφατασης και χρησεις αυτης - Google Patents

Παρασκευη ενεργης ακρως φωσφορυλιωμενης ανθρωπινης ν-ακετυλογαλακτοζαμινης-6-σουλφατασης και χρησεις αυτης

Info

Publication number
CY1118934T1
CY1118934T1 CY20171100207T CY171100207T CY1118934T1 CY 1118934 T1 CY1118934 T1 CY 1118934T1 CY 20171100207 T CY20171100207 T CY 20171100207T CY 171100207 T CY171100207 T CY 171100207T CY 1118934 T1 CY1118934 T1 CY 1118934T1
Authority
CY
Cyprus
Prior art keywords
sulfathase
phosphorlilened
acetylgactozamine
extremely
activity
Prior art date
Application number
CY20171100207T
Other languages
English (en)
Inventor
Vish Koppaka
Michel Claude Vellard
Augustus O Okhamafe
Kidisti Araya
Original Assignee
Biomarin Pharmaceutical Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharmaceutical Inc. filed Critical Biomarin Pharmaceutical Inc.
Publication of CY1118934T1 publication Critical patent/CY1118934T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06004—N-Acetylgalactosamine-6-sulfatase (3.1.6.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει συνθέσεις ενεργής άκρως φωσφορυλιωμένης ανθρώπινης Ν-ακετυλογαλακτοζαμίνης-6-σουλφατάσης (GALNS), και φαρμακευτικές συνθέσεις και φαρμακοτεχνικές μορφές αυτής, μεθόδους παραγωγής και καθαρισμού GALNS και χρήσης της στη διάγνωση, πρόληψη, ή θεραπεία ασθενειών και καταστάσεων, συμπεριλαμβανομένων συγκεκριμένα λυσοσωμικών ασθενειών αποθήκευσης που προκαλούνται από, ή συνδέονται με ανεπάρκεια του ενζύμου GALNS, π.χ., Βλεννοπολυσακχαρίδωση IVa (MPS IVa ή σύνδρομο Morquio A).
CY20171100207T 2010-07-22 2017-02-15 Παρασκευη ενεργης ακρως φωσφορυλιωμενης ανθρωπινης ν-ακετυλογαλακτοζαμινης-6-σουλφατασης και χρησεις αυτης CY1118934T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36671410P 2010-07-22 2010-07-22
PCT/US2011/045011 WO2012012718A2 (en) 2010-07-22 2011-07-22 Manufacture of active highly phosphorylated human n-acetylgalactosamine-6-sulfatase and uses thereof

Publications (1)

Publication Number Publication Date
CY1118934T1 true CY1118934T1 (el) 2018-01-10

Family

ID=44543776

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100207T CY1118934T1 (el) 2010-07-22 2017-02-15 Παρασκευη ενεργης ακρως φωσφορυλιωμενης ανθρωπινης ν-ακετυλογαλακτοζαμινης-6-σουλφατασης και χρησεις αυτης

Country Status (28)

Country Link
US (3) US8765437B2 (el)
EP (1) EP2595650B1 (el)
JP (2) JP6030553B2 (el)
KR (2) KR101949906B1 (el)
CN (1) CN103037895B (el)
AR (2) AR082319A1 (el)
AU (1) AU2011280937B2 (el)
BR (1) BR112013001558B1 (el)
CA (2) CA3146151A1 (el)
CL (2) CL2013000219A1 (el)
CY (1) CY1118934T1 (el)
DK (1) DK2595650T3 (el)
ES (1) ES2616263T3 (el)
HR (1) HRP20170245T1 (el)
HU (1) HUE033163T2 (el)
IL (2) IL224125B (el)
LT (1) LT2595650T (el)
MX (1) MX341838B (el)
PE (3) PE20131140A1 (el)
PL (1) PL2595650T3 (el)
PT (1) PT2595650T (el)
RS (1) RS55669B1 (el)
RU (1) RU2607376C2 (el)
SG (1) SG187580A1 (el)
SI (1) SI2595650T1 (el)
SM (1) SMT201700106B (el)
WO (1) WO2012012718A2 (el)
ZA (1) ZA201300286B (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2245145T1 (sl) * 2008-01-18 2017-05-31 Biomarin Pharmaceutical Inc. Izdelava aktivnih visoko fosforiliranih humanih encimov lizosomske sulfataze in njihova uporaba
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
WO2013119715A1 (en) * 2012-02-07 2013-08-15 Saint Louis University Determination of immunogenic peptides in lysosomal enzymes and induction of oral tolerance
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US11529397B2 (en) 2018-01-22 2022-12-20 Saint Louis University Method of treating mucopolysaccharidosis type IVA
EP2970380B1 (en) 2013-03-13 2018-05-02 Shire Human Genetic Therapies, Inc. Method of characterizing lysosomal enzymes
DK2968494T3 (en) * 2013-03-13 2019-03-04 Seattle Genetics Inc ACTIVATED CARBON FILTERING FOR CLEANING BENZODIAZEPINE ADCs
WO2014201220A1 (en) * 2013-06-12 2014-12-18 The Board Of Trustees Of The University Of Illinois Methods for detecting prostate cancer
JP2016529885A (ja) 2013-07-12 2016-09-29 イー・エム・デイー・ミリポア・コーポレイシヨン 活性炭を使用して標的タンパク質を含む試料からのウイルス除去を決定する方法
US20170191041A1 (en) * 2014-07-11 2017-07-06 Biostrategies LC Materials and methods for treating disorders associated with sulfatase enzymes
US10472615B2 (en) 2016-01-21 2019-11-12 Saint Louis University Reduced immunogenic proteins for lysosomal storage disorders
JP2019515677A (ja) 2016-04-26 2019-06-13 アール．ピー．シェーラー テクノロジーズ エルエルシー 抗体複合体ならびにそれを作製および使用する方法
US11584777B2 (en) 2017-08-31 2023-02-21 Green Cross Corporation Method for purifying a sulfatase protein
RU2763990C2 (ru) * 2020-02-19 2022-01-12 Акционерное общество "ГЕНЕРИУМ" Клетка, продуцирующая с высокой эффективностью активный белок арилсульфатазу в, и способ получения этой клетки
US20230193205A1 (en) * 2020-04-19 2023-06-22 Figene, Llc Gene modified fibroblasts for therapeutic applications
WO2023150387A1 (en) * 2022-02-07 2023-08-10 M6P Therapeutics, Inc. Compositions comprising acid alpha glucosidase and methods of use thereof
TW202403043A (zh) * 2022-03-18 2024-01-16 美商健臻公司 重組人類酸性鞘磷脂酶醫藥組合物及方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5186941A (en) 1983-05-06 1993-02-16 Vestar, Inc. Vesicle formulation for the controlled release of therapeutic agents
JPS62122588A (ja) 1985-11-22 1987-06-03 Taiyo Fishery Co Ltd 純コンドロイチナ−ゼの製造法
US6048729A (en) 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
NZ245015A (en) 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW492882B (en) 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
RU2195492C2 (ru) * 2000-09-04 2002-12-27 Институт физиологии Коми научного центра Уральского отделения РАН Способ получения пектолитического ферментного препарата
SG141239A1 (en) 2001-01-26 2008-04-28 Selexis Sa Matrix attachment regions and methods for use thereof
KR101035043B1 (ko) * 2002-07-01 2011-05-19 아르키온 라이프 사이언씨즈 엘엘씨 글루코사민 및 ｎ-아세틸글루코사민의 제조를 위한 물질및 공정
NZ570201A (en) 2003-02-11 2011-03-31 Shire Human Genetic Therapies Diagnosis and treatment of multiple sulfatase deficiency and other using a formylglycine generating enzyme (fge)
JP2007277094A (ja) * 2004-06-29 2007-10-25 Chemo Sero Therapeut Res Inst 改変ダニ主要アレルゲン含有医薬組成物
JP2008525032A (ja) * 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド 組換えヒト成長ホルモンを発現及び精製するための方法
AU2007240732B2 (en) * 2006-04-21 2013-07-04 Amgen, Inc. Buffering agents for biopharmaceutical formulations
US20080231439A1 (en) 2007-03-22 2008-09-25 Inventec Corporation Activity Detection Circuit for a Storage Device
SG10201604258YA (en) * 2007-11-30 2016-07-28 Abbvie Biotechnology Ltd Anti-tnf antibody formulations
SI2245145T1 (sl) * 2008-01-18 2017-05-31 Biomarin Pharmaceutical Inc. Izdelava aktivnih visoko fosforiliranih humanih encimov lizosomske sulfataze in njihova uporaba
US7722865B2 (en) * 2008-01-18 2010-05-25 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation

Also Published As

Publication number Publication date
RU2013107765A (ru) 2014-08-27
WO2012012718A2 (en) 2012-01-26
IL260282B (en) 2020-05-31
HUE033163T2 (en) 2017-11-28
AU2011280937A1 (en) 2013-01-31
KR20130105605A (ko) 2013-09-25
RU2607376C2 (ru) 2017-01-10
KR101598897B1 (ko) 2016-03-03
PE20171799A1 (es) 2017-12-28
CN103037895B (zh) 2016-11-09
CL2017000498A1 (es) 2017-11-24
CL2013000219A1 (es) 2014-07-11
IL224125B (en) 2019-02-28
MX2013000908A (es) 2013-07-05
LT2595650T (lt) 2017-03-10
PE20171798A1 (es) 2017-12-28
CN103037895A (zh) 2013-04-10
US20160186149A1 (en) 2016-06-30
DK2595650T3 (en) 2017-02-27
ZA201300286B (en) 2014-03-26
EP2595650A2 (en) 2013-05-29
PT2595650T (pt) 2017-02-22
US20140341878A1 (en) 2014-11-20
SG187580A1 (en) 2013-03-28
CA2805673C (en) 2022-04-05
KR101949906B1 (ko) 2019-04-22
RS55669B1 (sr) 2017-06-30
US8765437B2 (en) 2014-07-01
HRP20170245T1 (hr) 2017-04-21
PL2595650T3 (pl) 2017-06-30
ES2616263T3 (es) 2017-06-12
SI2595650T1 (sl) 2017-04-26
JP2013532986A (ja) 2013-08-22
CA3146151A1 (en) 2012-01-26
US8940513B2 (en) 2015-01-27
US20120189605A1 (en) 2012-07-26
BR112013001558A2 (pt) 2020-08-04
SMT201700106B (it) 2017-03-08
BR112013001558B1 (pt) 2022-08-16
JP6030553B2 (ja) 2016-11-24
CA2805673A1 (en) 2012-01-26
MX341838B (es) 2016-09-05
AR082319A1 (es) 2012-11-28
EP2595650B1 (en) 2016-11-16
US9567572B2 (en) 2017-02-14
WO2012012718A3 (en) 2012-04-05
KR20150038715A (ko) 2015-04-08
JP2016178950A (ja) 2016-10-13
PE20131140A1 (es) 2013-10-17
IL260282A (en) 2018-07-31
AR119552A2 (es) 2021-12-29
AU2011280937B2 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
CY1118934T1 (el) Παρασκευη ενεργης ακρως φωσφορυλιωμενης ανθρωπινης ν-ακετυλογαλακτοζαμινης-6-σουλφατασης και χρησεις αυτης
CY1118984T1 (el) Παρασκευη ενεργων, ακρως φωσφορυλιωμενων, ανθρωπινων λυσοσωμικων ενζυμων σουλφατασης και χρησεις αυτων
CY1119596T1 (el) Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης
CY1122128T1 (el) Θεραπεια ενζυμικης αντικαταστασης με κλιμακωση δοσης για αντιμετωπιση ανεπαρκειας σε οξινη σφιγγομυελιναση
BR112015010663A8 (pt) formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
AR081681A1 (es) METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
CY1116424T1 (el) Παραγωγο αδενινης ως αναστολεας ρι3κ
AU2011274619A8 (en) miRNA and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated BRAF pathway
BRPI0507440A (pt) fabricação de enzimas lisossomais altamente fosforiladas e uso das mesmas
AU2012253757A8 (en) Partially saturated tricyclic compounds and methods of making and using same
AU2012253759A8 (en) Tricyclic sulfonamide compounds and methods of making and using same
BRPI0808775A2 (pt) compostos e composições como moduladores de atividade de gpr119
NZ605871A (en) Treatment of sanfilippo syndrome type b
MX2019002669A (es) Composicion farmaceutica para usarse en el tratamiento de la malnutricion en un sujeto que exhibe un trastorno de espectro de autismo (asd).
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
HN2011003011A (es) Composiciones sublinguales de dexmedetomidina y metodos de uso de ellas
TR200806298A2 (tr) Farmasötik formülasyon
IN2012DN02471A (el)
EA201171043A1 (ru) Композиции и способы длительной терапии с применением аминопиридинов
CY1116840T1 (el) Χρηση 24-norudca
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
WO2010135521A3 (en) Compositions and methods for the therapy and diagnosis of influenza
ATE455789T1 (de) Substituierte nonadepsipeptide